Literature DB >> 9427570

Antiendothelial cell antibodies in thromboangiitis obliterans.

J Eichhorn1, D Sima, C Lindschau, A Turowski, H Schmidt, W Schneider, H Haller, F C Luft.   

Abstract

The occurrence of autoimmune phenomena in 28 patients with thromboangiitis obliterans (Buerger's disease) was determined. The following were sought: antineutrophil cytoplasmic antibodies against proteinase 3 (cANCA) and myeloperoxidase (pANCA), antinuclear antibodies, anti-Ro antibodies, anticardiolipin antibodies, and antiendothelial cell antibodies (AECA). For the last, an enzyme-linked immunosorbent assay was developed which verified the presence of the AECA phenomenon with immunofluorescence and confocal microscopy. Seven patients with active disease had AECA titers of 1,857 +/- 450 arbitrary units (AU) compared with 126 +/- 15 AU in 30 normal control subjects (P < 0.001) and 461 +/- 41 AU in 21 patients in remission (P < 0.01). Antibodies from the sera of patients with active disease reacted not only with surface epitopes but also with sites within the cytoplasm of human endothelial cells. AECA may be useful in following disease activity and may play a role in the pathogenesis of thromboangiitis obliterans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427570     DOI: 10.1097/00000441-199801000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  14 in total

1.  Thromboangiitis Obliterans (Buerger's Disease).

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

2.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

3.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 4.  Thromboangiitis obliterans.

Authors:  Gregory Piazza; Mark A Creager
Journal:  Circulation       Date:  2010-04-27       Impact factor: 29.690

5.  Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study.

Authors:  Gert Baumann; Verena Stangl; Peter Klein-Weigel; Karl Stangl; Michael Laule; Kathrin Enke-Melzer
Journal:  Clin Res Cardiol       Date:  2011-03-05       Impact factor: 5.460

6.  Are There Any Objections against Our Hypothesis That Buerger Disease Is an Infectious Disease?

Authors:  Takehisa Iwai; Makoto Umeda; Yoshinori Inoue
Journal:  Ann Vasc Dis       Date:  2012

7.  Thromboangiitis Obliterans (Buerger's Disease).

Authors:  Nicholas R Sinclair; Donald R Laub
Journal:  Eplasty       Date:  2015-04-10

Review 8.  Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.

Authors:  Abhishek Vijayakumar; Rahul Tiwari; Vinod Kumar Prabhuswamy
Journal:  Int J Inflam       Date:  2013-09-11

9.  The Association of HLA-A, B and DRB1 with Buerger's Disease.

Authors:  Abbas Shapouri-Moghaddam; Mojgan Mohammadi; Hamid Reza Rahimi; Habibolah Esmaeili; Mahmoud Mahmoudi; Mohammad-Hadi Saeed Modaghegh; Jalil Tavakol Afshari
Journal:  Rep Biochem Mol Biol       Date:  2019-07

10.  Thromboangiitis obliterans in two brothers.

Authors:  Qi-Lin Li; Dan-Hua He; Yong-Hua Huang; Mu Niu
Journal:  Exp Ther Med       Date:  2013-06-14       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.